Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, CG Oncology, Inc. Common stock (CGON) has a Wall Street consensus price target of $79.00, based on estimates from 9 covering analysts. With the stock currently trading at $58.80, this represents a potential upside of +34.4%. The company has a market capitalization of $4.60B.
Analyst price targets range from a low of $70.00 to a high of $93.00, representing a 29% spread in expectations. The median target of $75.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CGON trades at a trailing P/E of -41.7x. Analysts expect EPS to grow -34.4% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CGON stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CGON is $79, representing 34.4% upside from the current price of $58.8. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CGON has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $79 implies 34.4% upside from current levels.
CGON's current price is $58.8 with a consensus target of $79 (34.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $93 for CGON, while the most conservative target is $70. The consensus of $79 represents the median expectation. These targets typically reflect 12-month expectations.
CGON is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CGON stock forecast based on 9 Wall Street analysts shows a consensus price target of $79, with estimates ranging from $70 (bear case) to $93 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CGON, with a "Buy" consensus rating and $79 price target (34.4% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CGON analyst price targets range from $70 to $93, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $79 consensus represents the middle ground.